Once-daily osmotic controlled-release (OROS) methylphenidate (Concerta) in the treatment of 407 children, aged 6-13 years, with ADHD who were known MPH responders, was evaluated in a 24-month multicenter, open-label, nonrandomized study, and reported from the Massachusetts General Hospital, Boston. In 289 (71%) who completed 12 months’treatment, OROS MPH was well tolerated and effectiveness was maintained up to 12 months. Of 118 who failed to complete the trial period, 31 (7.6%) discontinued for lack of effectiveness, and 28 (6.9%) for adverse events, including tics (7), and insomnia (5). New onset of tics occurred in 23 (6.4%) subjects. [1]
OROS Methylphenidate Long-Term Study in ADHD
DOI: https://doi.org/10.15844/pedneurbriefs-17-5-9 | Journal eISSN: 2166-6482
Language: English
Page range: 40 - 40
Published on: May 1, 2003
Published by: Pediatric Neurology Briefs Publishers
In partnership with: Paradigm Publishing Services
Keywords:
© 2003 J Gordon Millichap, published by Pediatric Neurology Briefs Publishers
This work is licensed under the Creative Commons Attribution 4.0 License.